Platelet Rich Plasma and Growth Factor Treatments 2.01.24
Policy 2.01.24, Platelet Rich Plasma and Growth Factor Treatments, states that platelet-rich plasma (PRP) and autologous platelet-derived preparations, including basic fibroblast growth factor, epidermal growth factor, and placental angiogenic growth factors, are investigational for all indications. The 01/22/26 annual update changed the policy title and deleted the policy statements for becalpermin gel. The policy also states that the AAOS guidelines for osteoarthritis of the hip and glenohumeral joint, and for rotator cuff injuries, do not recommend PRP for these conditions.